Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.

Biotech Giants' SG&A Expenses: A Decade of Growth

__timestampTravere Therapeutics, Inc.Verona Pharma plc
Wednesday, January 1, 2014596446961802274
Thursday, January 1, 2015795410002512761
Friday, January 1, 2016980150002894488
Sunday, January 1, 20171039580008096274
Monday, January 1, 20181036540007985229
Tuesday, January 1, 20191289510008994597
Wednesday, January 1, 202013579900029772000
Friday, January 1, 202114988300033907000
Saturday, January 1, 202222020600026579000
Sunday, January 1, 202326554200049868547
Loading chart...

Unleashing insights

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Verona Pharma plc and Travere Therapeutics, Inc. from 2014 to 2023. Over this period, Travere Therapeutics consistently outspent Verona Pharma, with its SG&A expenses growing by approximately 345%, from $59.6 million in 2014 to $265.5 million in 2023. In contrast, Verona Pharma's expenses increased by a staggering 2,667%, from a modest $1.8 million to $49.9 million. This dramatic rise reflects Verona's aggressive expansion strategy. While Travere's expenses indicate steady growth, Verona's sharp increase suggests a significant shift in business operations. Understanding these trends provides valuable insights into each company's strategic priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025